Serum B-Cell Maturation Antigen Reflects Disease Status in a Patient Who Developed Nonsecretory Multiple Myeloma: A Case Report
Authors:
Open Access
- 18 June 2024
- journal article
- research article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 17 (1) , 747-752
Abstract
Introduction: Multiple myeloma (MM) is an incurable bone marrow (BM)-based cancer involving clonal plasma cells. Most patients show elevated levels of serum monoclonal protein (sMP) and kappa or lambda serum free light chains (sFLCs) at diagnosis. However, around 1–2% of patients, termed nonsecretory, do not produce these biomarkers. As the disease progresses, more patients may become unevaluable using conventional markers, requiring invasive and expensive procedures like BM biopsies and positron emission tomography-computed tomography (PET-CT) scans for assessment and highlighting the need for alternative methods to monitor disease progression. Case Presentation: We present a case report of an MM patient who developed nonsecretory disease during his second line of treatment when he complained of new rib pain; progressive disease was then confirmed on a PET-CT scan. The patient showed an increase in his serum B-cell maturation antigen (sBCMA) levels whereas his conventional myeloma markers did not detect disease activity (sMP remained undetectable and involved sFLC level was normal). After starting a new treatment regimen, his rib pain disappeared, PET-CT scan improved, and sBCMA levels decreased. Upon relapse, he developed increased rib pain with a rising sBCMA level; his conventional myeloma markers did not detect disease activity. After changing to a new regimen, his rib pain improved, and this was accompanied by a decrease in his sBCMA levels. Conclusion: Thus, this case exemplifies the potential for sBCMA to provide a non-invasive method for monitoring MM patients who develop nonsecretory disease.Keywords
This publication has 10 references indexed in Scilit:
- Outcomes after biochemical or clinical progression in patients with multiple myelomaBlood Advances, 2023
- Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New TherapyTargeted Oncology, 2021
- Estimating a normal reference range for serum B‐cell maturation antigen levels for multiple myeloma patientsBritish Journal of Haematology, 2020
- Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myelomaAnnals of Hematology, 2020
- The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple MyelomaTargeted Oncology, 2017
- Changes in Serum B-Cell Maturation Antigen Levels Are a Rapid and Reliable Indicator of Treatment Efficacy for Patients with Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2017
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patientsHaematologica, 2016
- Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survivalBritish Journal of Haematology, 2012
- Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myelomaBlood, 2001
- Nonsecretory Multiple MyelomaActa Haematologica, 1985